

Abu Dhabi to launch multi-omics research institute in partnership with GSK

16 April 2025 | News

To embed early-stage discovery research within the UAE for the first time



During Abu Dhabi Global Health Week (ADGHW), the Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, and the Abu Dhabi Investment Office (ADIO) signed a Memorandum of Understanding (MoU) with GSK, global biopharmaceutical leader, to collaborate on a Multi-omics Research Institute in Abu Dhabi.

This transformative collaboration aims to accelerate oncology-focused genomic science and precision medicine, enhancing diversification and global representation in genomic research to improve cancer patient outcomes.

Multi-omics is a research approach that studies different biological molecules, such as genes, RNA, proteins, and metabolites, to understand how they interact in an organism. By combining data from these various areas, scientists can gain a more complete view of biological processes and improve insights into health and disease.

By leveraging Abu Dhabi's cutting-edge biotechnology and genomics infrastructure, this multinational initiative will embed early-stage discovery research within the UAE for the first time, fostering scientific innovation in oncology and enhancing diversity in genomic research to ultimately benefit cancer patients.

Badr Al-Olama, Director General of Abu Dhabi Investment Office (ADIO), said, "The launch of a multi-omics research institute marks a defining step in Abu Dhabi's evolution as a global centre for health innovation. By embedding discovery-stage science into our ecosystem, we are supporting critical oncology research while reinforcing the emirate's leadership in health innovation, biotechnology, and precision medicine. Driven by a commitment to scientific excellence and cross-sector partnerships, this collaboration will translate research into long-term value, not only for Abu Dhabi, but for the future of global healthcare."